Development and applications of allosteric reverse transcriptase inhibitors for Genome engineering

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15521
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Infectious disease medicine
• Research Institution: Kumamoto University
• Principal Investigator: Nakamura Tomofumi 熊本大学, 大学院生命科学研究部(医), 研究員 (00772526)
• Research Collaborator: Otsu Sachiko
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: HIV-1感染症 / CRISPA-Cas9 / 遺伝子編集

Outline of Final Research Achievements

We produced a new assay system for detecting genome editing efficiency of CRISPA-Cas9 (SpCas9) by measuring fluorescent intensity emitting from the fluorescent proteins (Venus) expressed in 293T and COS7 cells, and then investigated and evaluated some compounds that were reported as affecting the genome editing (DNA repair) efficiency. By measuring the Venus fluorescent intensity in the cells using microplate reader and FCM, it was possible to acquire quantitatively the efficiency of Venus genome editing by SpCas9. When we analyzed the compounds of AZT, SCR7, and L755507 reported as genome editing enhancers or inhibitors by using the assay system, significant change of Venus intensity in the presence of the compounds were not detected.

Free Research Field

感染症、血液内科